Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732659 | 1.00 | SIGMAR1 (0.77) | SIGMAR1ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL29447362 | 1.00 | SIGMAR1 (0.77) | SIGMAR1ALDH1A1SMN1; SMN2TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL16825190 | 0.98 | SIGMAR1 (0.74) | SIGMAR1ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL29447340 | 0.98 | SIGMAR1 (0.79) | SIGMAR1ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL3169406 | 0.98 | SIGMAR1 (0.79) | SIGMAR1ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL29668629 | 0.94 | SIGMAR1 (0.79) | SIGMAR1ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL20238106 | 0.94 | SIGMAR1 (0.79) | SIGMAR1ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL26125697 | 0.88 | SIGMAR1 (0.65) | SIGMAR1ALDH1A1SMN1; SMN2TDP1KDM4E | |
| Ammonia Solution, Strong SCHEMBL2926473 | 0.86 | LTA4H (0.64) | SIGMAR1ALDH1A1SMN1; SMN2TDP1KDM4E | |
| SCHEMBL11339852 | 0.86 | PRMT6 (0.78) | ALDH1A1SMN1; SMN2TDP1KDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105829293-B | New piperidine carbamyl class compound, preparation method and its usage | 中国人民解放军军事医学科学院毒物药物研究所 | 2018-11-09 | — | — | CN | claimed |
| CN-105829293-A | Novel piperidine carboxamide compound, preparation method, and usage thereof | 中国人民解放军军事医学科学院毒物药物研究所 | 2016-08-03 | — | — | CN | claimed |
| EP-3083584-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-10-26 | — | — | EP | disclosed |
| CN-105829293-A | Novel piperidine carboxamide compound, preparation method, and usage thereof | 中国人民解放军军事医学科学院毒物药物研究所 | 2016-08-03 | — | — | CN | disclosed |
| WO-2015090232-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-25 | — | — | WO | disclosed |
| WO-2011163518-A1 | PYRAZOLO [1, 5 -A] PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-7939672-B2 | Phenylacetate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by activation of T-type calcium ion channel containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-10 | — | — | US | disclosed |
| US-20100056545-A1 | NOVEL PHENYLACETATE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES INDUCED BY ACTIVATION OF T-TYPE CALCIUM ION CHANNEL CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-03-04 | — | — | US | disclosed |
| WO-2009158587-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056545-A1 | NOVEL PHENYLACETATE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES INDUCED BY ACTIVATION OF T-TYPE CALCIUM ION CHANNEL CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CACNA1A, CACNA1G, CACNA1H | SIGMAR1 559/4885ALDH1A1 936/4885SMN1; SMN2 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.